title: [Myocardial cytoprotectors, a reserve therapeutic modality for patients with stable angina of effort].
abstract: The study included 1418 patients with FC I-IV stable angina of effort (42.4% men and 57.6% women, mean age 74.6 +/- 1.2 years). The possibility to supplement standard therapy with myocardial cytoprotectors (trimetasidin, mexidol, qudesan) was estimated in 4 groups of patients from the severity of pain syndrome, chronic cardiac insufficiency, and heart rhythm disturbances.
authors.forename: V B
authors.initials: VB
authors.lastname: Simonenko
authors.forename: O S
authors.initials: OS
authors.lastname: Stepaniants
authors.forename: A N
authors.initials: AN
authors.lastname: Teslia
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000473:pathology*; D019610:Cytoprotection; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009206:Myocardium / Q000473:pathology*; D010847:Picolines / Q000627:therapeutic use*; D014292:Trimetazidine / Q000627:therapeutic use*; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010847:Picolines; D014451:Ubiquinone; C070020:emoxypine succinate; C024989:coenzyme Q10; D014292:Trimetazidine